Thymosin Beta-4 (Tβ4) Benefits: What Studies Report

Thymosin Beta-4 (Tβ4) is a small, naturally occurring peptide best known as an intracellular actin-sequestering molecule. Most of what is publicly claimed about it comes from preclinical research — cell culture, rodent models and ex vivo tissue — rather than from large human trials. This page groups the published literature by outcome domain and describes what the study designs were, which populations were involved, and which direction of effect researchers reported. It does not recommend use of any kind. For background on the molecule itself, see the Thymosin Beta-4 overview.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical decision, symptom or treatment.

Evidence Map: Domains Where Tβ4 Has Been Studied

Cardiac Repair After Ischemia

The cardiac literature is the domain where Tβ4 has moved furthest toward human testing. A 2025 report in Cardiovascular Research described recombinant human thymosin beta 4 improving ischemic cardiac dysfunction in mice and in patients with acute ST-segment elevation myocardial infarction after reperfusion (PMID 41229390). Researchers combined an animal arm with a human arm, which is unusual for this peptide; the study therefore represents the clearest human signal in this citation set, while still being a single report rather than a body of replicated trial evidence (PMID 41229390).

Earlier work was summarized in a 2016 review chapter titled Cardioprotection by Thymosin Beta 4, which collected preclinical findings on the peptide's reported cardioprotective roles (PMID 27450736). Reviews of this kind aggregate laboratory and animal results and do not themselves establish clinical outcomes in people (PMID 27450736).

A 2025 methodological paper examined living myocardial slices as a model for testing cardiac pro-reparative gene therapies, a human-relevant ex vivo platform used to evaluate repair-oriented interventions before animal or clinical work (PMID 40143546). The study assessed a testing system rather than patient outcomes, and results from such platforms are explicitly preclinical (PMID 40143546).

Eye and Ocular Surface

Corneal wound healing

A 2025 study in Investigative Ophthalmology & Visual Science reported that an engineered tandem thymosin peptide promoted corneal wound healing (PMID 41235866). Two points matter for interpretation: the molecule tested was an engineered tandem construct rather than unmodified Tβ4, and the work was laboratory and animal research, not a human trial (PMID 41235866).

Bacterial keratitis

A 2023 paper in International Immunopharmacology framed thymosin beta 4 as a potential novel adjunct treatment for bacterial keratitis — that is, an addition to antimicrobial therapy rather than a replacement for it (PMID 37018981). The word potential in that framing reflects the preclinical, hypothesis-generating stage of the work (PMID 37018981).

Dry eye disease

Dry eye is frequently named in popular claims about Tβ4, but this citation set contains no Tβ4 dry-eye trial. The relevant 2025 paper in Signal Transduction and Targeted Therapy identified glutamine as a potential therapeutic target in dry eye disease, which is a different molecular target entirely (PMID 39837870). It illustrates how active the ocular surface field is, but it cannot be read as evidence for Tβ4 in dry eye (PMID 39837870).

Neurological Injury and Neurodegeneration

A 2015 expert-opinion review discussed thymosin β4 as a restorative/regenerative therapy for neurological injury and neurodegenerative diseases (PMID 25613458). Reviews in this format describe the state of a research programme — typically rodent injury models and mechanistic work — and the framing of a candidate as "restorative/regenerative" describes a research hypothesis rather than a demonstrated clinical outcome (PMID 25613458). No human neurological trial of Tβ4 appears in this verified citation set.

Inflammation, Sepsis and Actin Regulation

Much of the mechanistic interest in Tβ4 stems from its role in actin dynamics. A 2018 review in Expert Opinion on Biological Therapy examined thymosin beta 4 regulation of actin in sepsis, linking the peptide's core biochemical function to a critical-illness context (PMID 29508629). Readers sometimes convert this kind of mechanistic discussion into general "anti-inflammatory" claims; the review described a mechanism and a research direction, not an approved sepsis treatment (PMID 29508629).

Tendon, Muscle and Athletic Performance Claims

Tβ4 and its fragment analogues are widely discussed in sports settings, so the review literature on peptides in musculoskeletal medicine is directly relevant. A 2026 review in Sports Medicine addressed the safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance (PMID 41966639). A companion 2026 review in The American Journal of Sports Medicine covered peptide supplements and their therapeutic applications in sports medicine (PMID 42578445). Both were narrative/evidence reviews rather than trials of a single peptide, and the distinction they draw between approved and unapproved products is central: unapproved peptides are described as lacking the regulatory evidence base that approved products carry (PMID 41966639).

Human data on one peptide do not transfer to another. A 2021 report in Alternative Therapies in Health and Medicine described intra-articular injection of BPC 157 for multiple types of knee pain — a different peptide, a different route and a different clinical question (PMID 34324435). It is cited here only because BPC 157 and Tβ4 are routinely discussed together, and that report says nothing about Tβ4 outcomes (PMID 34324435).

Claims With Little or No Support in This Literature

• Hair growth, skin appearance and "anti-aging": no study in this verified citation set measured these outcomes; the nearest reparative evidence concerns cornea (PMID 41235866) and heart tissue (PMID 27450736), which are not interchangeable with cosmetic endpoints.
• Dry eye relief: the dry-eye paper in this set investigated glutamine, not Tβ4 (PMID 39837870).
• Faster tendon or ligament recovery in athletes: the sports-medicine reviews described limited human evidence for unapproved peptide therapies used for musculoskeletal injury (PMID 41966639, PMID 42578445).
• Standardized human regimens: no dosing schedule for Tβ4 is reproduced on this page, because the verified papers here were not dose-ranging trials; the one report with a human arm was described as recombinant human thymosin beta 4 in patients after STEMI reperfusion (PMID 41229390).

Thymosin Beta-4 Safety and Adverse Events: What Studies Report

Safety information in this citation set is sparse and indirect. The 2026 Sports Medicine review explicitly paired safety with efficacy when assessing approved and unapproved peptide therapies, signalling that both remain open questions for unapproved compounds used in athletic contexts (PMID 41966639). The 2026 American Journal of Sports Medicine review similarly addressed peptide supplements in sports medicine as a category requiring clinical scrutiny (PMID 42578445).

A separate line of mechanistic concern comes from oncology research: a 2025 study in Cellular Signalling reported that the Tβ4/SLC7A11 signalling pathway regulated breast cancer evolution (PMID 40912522). That work was a laboratory signalling study, not a clinical safety analysis, but it is the kind of finding researchers cite when discussing why pro-angiogenic and pro-migratory peptides require careful evaluation (PMID 40912522).

No systematic adverse-event tabulation for Tβ4 appears in the verified papers listed here. Absence of reported harm in a small preclinical literature is not the same as demonstrated safety.

How to Read This Evidence

1. Check the organism. Most findings described above came from cells, rodents or ex vivo tissue, including the myocardial slice platform study (PMID 40143546).
2. Check the molecule. Engineered constructs are not identical to native Tβ4, as in the tandem thymosin peptide corneal study (PMID 41235866).
3. Check the design. Expert-opinion reviews summarize a field; they do not generate new outcome data (PMID 25613458, PMID 29508629).
4. Check whether humans were included. In this set, only the 2025 cardiovascular report described patients alongside mice (PMID 41229390).

Taken together, the papers cited on this page describe Tβ4 as an actively investigated repair-associated peptide with its most advanced evidence in cardiac ischemia (PMID 41229390) and ocular surface models (PMID 37018981), and as a compound whose use outside research settings is not supported by the sports-medicine review literature (PMID 42578445). Anyone with a cardiac, ocular, neurological or musculoskeletal condition should discuss it with a licensed physician.

References

• Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion (Cardiovascular Research, 2025)
• Cardioprotection by Thymosin Beta 4 (Vitamins and Hormones, 2016)
• Living myocardial slices as a model for testing cardiac pro-reparative gene therapies (Molecular Therapy, 2025)
• Engineered Tandem Thymosin Peptide Promotes Corneal Wound Healing (Investigative Ophthalmology & Visual Science, 2025)
• Thymosin beta 4: A potential novel adjunct treatment for bacterial keratitis (International Immunopharmacology, 2023)
• Identification of glutamine as a potential therapeutic target in dry eye disease (Signal Transduction and Targeted Therapy, 2025)
• Thymosin β4 as a restorative/regenerative therapy for neurological injury and neurodegenerative diseases (Expert Opinion on Biological Therapy, 2015)
• Thymosin beta 4 regulation of actin in sepsis (Expert Opinion on Biological Therapy, 2018)
• Mechanistic study of the Tβ4/SLC7A11 signaling pathway regulating breast cancer evolution (Cellular Signalling, 2025)
• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Sports Medicine, 2026)
• Peptide Supplements and Their Therapeutic Applications in Sports Medicine (The American Journal of Sports Medicine, 2026)
• Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain (Alternative Therapies in Health and Medicine, 2021)